39例肺转移瘤立体定向放射治疗的疗效分析 5%和93.5%(P=0.023)。全组中位生存时间为21.6个月(3.4~62.2个月)。1年和2年的总生存率(overall survival,OS)、局控率、无进展生存率分别为78.9%和48.2%、88.4%和82.8%、65.0%和39.3%,
基于4个网页-相关网页
10年累计发生组织学转变的累计风险为22%(95% CI 15-29),在发生转化后3年的总生存率是71%(95% CI 58-87%)。
The 10-year cumulative risk of histological transformation was 22% (95%CI 15-29) and the 3-year OS after transformation was 71% (95%CI 58-87%).
无论如何,除了90年代初期十分高龄的患者总的生存率还是都有所提高。
However, survival has improved in all but the very oldest ages since the early 1990s.
两组患者的5年总的生存率都接近70%以及无复发的生存率大约为62%。
In both groups, overall 5-year survival rate was approximately 70% and recurrence-free survival rate was about 62%.
应用推荐